[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657866":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":33,"studyPopulation":25,"armGroups":34,"interventions":41,"overallOfficials":47,"centralContacts":52,"locations":61,"responsibleParty":81,"collaborators":25,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":91,"sex":92,"minAge":93,"maxAge":25,"enrollmentInfo":94,"targetDuration":25,"studyType":97,"phases":98,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":117,"whyStopped":25,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},{"fullName":5,"class":6},"oasicare ApS","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":25},[9],{"measure":10,"description":11,"timeFrame":12},"Incidence of Grade 2 Perineal Tears","Proportion of eligible participants with a documented Grade 2 perineal tear. The numerator is the number of eligible participants with a documented Grade 2 perineal tear and the denominator is the number of eligible participants with known perineal tear grade. Grade 3 and Grade 4 perineal tears are not counted as Grade 2 events and will be reported separately and included in exploratory analyses of Grade ≥2 perineal tears.","Immediately after vaginal childbirth",[14,17,21],{"measure":15,"description":16,"timeFrame":12},"Incidence of Grade ≥2 perineal tears","Proportion of eligible participants experiencing Grade 2, Grade 3 or Grade 4 perineal tears.",{"measure":18,"description":19,"timeFrame":20},"Successful ASISU use","Number and proportion of births in which ASISU use was attempted and successfully completed without device discontinuation.","During vaginal childbirth, assessed immediately after each delivery",{"measure":22,"description":23,"timeFrame":24},"ASISU non-use","Number and proportion of enrolled eligible births in which ASISU was not used, including documented reasons for non-use.","Through completion of the 3-month implementation period",null,{"allocation":27,"interventionModel":28,"interventionModelDescription":29,"primaryPurpose":30,"observationalModel":25,"timePerspective":25,"maskingInfo":31},"NA","SINGLE_GROUP","Single-group, prospective, non-randomized ward-level implementation study. ASISU is introduced into routine clinical practice following standardized staff training. Enrolled participants constitute the prospective post-implementation study population. Use of ASISU in an individual birth remains subject to clinical judgment and is not mandated in every enrolled participant. Clinical outcomes are compared descriptively with eligible historical pre-implementation routine-care data.","PREVENTION",{"masking":32,"maskingDescription":25,"whoMasked":25},"NONE","ASISU is a CE-marked, single-use perineal protection device intended for use during the second stage of vaginal childbirth.\n\nThis study prospectively introduces ASISU at ward level within routine maternity care and evaluates its implementation and clinical performance. Midwives and relevant clinical staff will receive standardized training in use of ASISU before implementation.\n\nApproximately 280 evaluable nulliparous participants undergoing eligible vaginal birth at ≥37 weeks of gestation will be prospectively enrolled. ASISU will be used within its intended purpose and according to the Instructions for Use.\n\nEnrollment does not mandate application of ASISU in every individual birth. The responsible clinical staff retain discretion regarding whether ASISU is used according to the clinical circumstances, maternal preference and routine care.\n\nProspective clinical data will include ASISU use, non-use and discontinuation, reasons for non-use or discontinuation, episiotomy, perineal tear degree and type, maternal birthing position, maternal characteristics and infant birth weight.\n\nThe primary clinical outcome is the incidence of Grade 2 perineal tears. Outcomes following implementation will be compared descriptively with an eligible historical pre-implementation reference cohort derived from routine-care data, provided compatible outcome definitions and denominators are available.\n\nImplementation outcomes include staff training and competency, integration into clinical workflow, successful device use, discontinuation and reasons for non-use.\n\nThe study does not involve randomization, blinding, use of ASISU outside its intended purpose, or additional invasive or burdensome clinical procedures.",[35],{"label":36,"type":37,"description":38,"interventionNames":39},"ASISU Ward-Level Implementation","EXPERIMENTAL","Participants enrolled following ward-level implementation of ASISU. ASISU is available for use during the second stage of vaginal childbirth according to its intended purpose and Instructions for Use. Application of ASISU in an individual birth remains subject to clinical judgment and is not mandated for every enrolled participant.",[40],"Device: Perineal protection device",[42],{"type":43,"name":44,"description":45,"armGroupLabels":46,"otherNames":25},"DEVICE","Perineal protection device","ASISU is a CE-marked, single-use perineal protection device intended for use during the second stage of vaginal childbirth. The device is used according to its intended purpose and Instructions for Use. Following ward-level implementation, application in an individual birth is determined by the responsible clinical staff based on clinical circumstances and routine care and is not mandated in every enrolled participant.",[36],[48],{"name":49,"affiliation":50,"role":51},"Lone Krebs, MD, PhD","Amager & Hvidovre Hospital","PRINCIPAL_INVESTIGATOR",[53,58],{"name":54,"role":55,"phone":56,"phoneExt":25,"email":57},"Bushra Shahida, PhD","CONTACT","+45 28262484","bushra@oasi.care",{"name":49,"role":55,"phone":59,"phoneExt":25,"email":60},"+45 3862 0705","lone.krebs@regionh.dk",[62],{"facility":50,"status":25,"city":63,"state":25,"zip":64,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":72,"contacts":73},"Hvidovre","2650","Denmark","DK",{"type":68,"coordinates":69},"Point",[70,71],12.47708,55.64297,{"lat":71,"lon":70},[74,75,76,79],{"name":49,"role":55,"phone":59,"phoneExt":25,"email":60},{"name":54,"role":55,"phone":25,"phoneExt":25,"email":57},{"name":77,"role":78,"phone":25,"phoneExt":25,"email":25},"Catharina Hein Hoffmann, MD","SUB_INVESTIGATOR",{"name":80,"role":78,"phone":25,"phoneExt":25,"email":25},"Nanna Bjerg Pagh, Midwife",{"type":82,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100657866","ward-level-implementation-and-post-market-clinical-follow-up-study-of-asisu-under-routine-clinical-practice-100657866",false,"NCT07844005","Ward-Level Implementation and Post-Market Clinical Follow-up Study of ASISU Under Routine Clinical Practice","Ward-Level Implementation and Observational Post-Market Clinical Follow-up Study of ASISU Under Routine Clinical Practice","ASISU-PMCF","Inclusion Criteria:\n\n* Nulliparous participant\n* Gestational age ≥37 completed weeks\n* Eligible for vaginal birth\n* Meets predefined study eligibility criteria -Written informed consent obtained before study-specific data collection -\n\nExclusion Criteria:\n\n* Birth requiring or proceeding to instrumental intervention for the primary efficacy endpoint. If such a conversion occurs after consent, the reason may still be summarized as an implementation interruption where recorded.\n\n  * Known perineal abnormality or complication incompatible with ASISU use or requiring surgical intervention during delivery.\n  * Births involving episiotomy.\n  * Planned caesarean section or intrapartum conversion to caesarean section for the clinical efficacy analysis.\n  * Birth in water.\n  * Genital warts (HPV\u002Fcondylomata) affecting the perineal area.\n  * Perineal varices.\n  * Active genital herpes outbreak.\n  * Known hypersensitivity or intolerance to ASISU device materials or adhesive.\n  * For the prospective observational cohort: inability or unwillingness to provide valid informed consent excludes the individual from enrolment and from inclusion of her individual-level data in the study dataset. It does not, in itself, constitute a clinical contraindication to routine use of ASISU.",true,"FEMALE","18 Years",{"count":95,"type":96},280,"ESTIMATED","INTERVENTIONAL",[27],"This is a single-center, prospective, non-randomized post-market clinical follow-up study evaluating the implementation and clinical performance of ASISU during routine vaginal childbirth. ASISU is a Conformité Européenne (CE)-marked medical device, single-use medical device intended to provide perineal protection during the second stage of vaginal childbirth.\n\nApproximately 280 nulliparous participants undergoing eligible vaginal birth at ≥37 weeks of gestation will be prospectively enrolled following ward-level implementation of ASISU.\n\nASISU will be used within its intended purpose and according to the Instructions for Use. Although ASISU is prospectively introduced at ward level as part of the study, use of ASISU in an individual birth remains subject to clinical judgment and is not mandated in every enrolled participant.\n\nThe study will evaluate implementation of ASISU in routine maternity care and clinical outcomes, including Grade 2 perineal tears. Outcomes following implementation will be compared descriptively with eligible historical pre-implementation routine-care data.",[101],"Perineal Trauma",[103,104,105,106,107,108,109,110,111,112,113,114,115,116],"Perineal tear","Perineal trauma","Vaginal childbirth","Perineal protection","ASISU","Medical device","Implementation science","Medical device implementation","Usability; Workflow integration","Feasibility","Midwifery","Maternity care","Appropriateness","Acceptability","NOT_YET_RECRUITING","2026-09-24",{"date":120,"type":121},"2026-09-28","ACTUAL",{"date":123,"type":96},"2026-10-19",{"date":125,"type":96},"2027-01-31",{"name":5,"class":6},1]